AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.

Also called NCT01118520

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 224 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01118520
  • EudraCT 2010-020226-17
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01118520. Randomized; triple masking; primary purpose treatment. Start 2011-09 (actual); primary completion 2015-04 (actual). Results posted on 2021-01-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Acronym
AARDVARK
Condition
Abdominal Aortic Aneurysm
Intervention (Drug)
perindopril arginine
Intervention (Drug)
amlodipine 5mgs
Intervention (Drug)
placebo
Lead sponsor
Imperial College London (class: other)
Collaborator
National Institute for Health Research, United Kingdom (class: other government)

Record details

Record id
cardio:ct-nct01118520
Content hash
ecf11ad52e8751dbe314dca65bf85b00d9ae315b2d727c62a13c1e233ae440a7